Embedded Files
My research is funded by a variety of sources. Several main projects are shown below, with links to the funding agencies.
Project Narrative: Long-term survivorship is now a real possibility for patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with the chimeric antigen receptor (CAR) T-cell therapy. Almost nothing is known about neurocognitive and patient-reported outcomes in patients undergoing this treatment, however. The current study will investigate longitudinal changes in these outcomes in the first year after CAR T-cell therapy compared to individuals without cancer.
Role: MPI.
Funding Agency: National Cancer Institute
Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and Behaviors
Project Narrative: Fatigue is a persistent problem affecting up to 90% of cancer patients, yet treatment options are limited. Advances in metabolomics and genomics offer an unprecedented opportunity to unravel the underlying biological mechanisms and to identify novel biomarkers of fatigue, which may be targets for therapeutic intervention. We will use the 3-P (Predisposing, Precipitating, Prepetuating) model to combine genomics, metabolomics, inflammatory markers and behaviors to comprehensively examine contributors of cancer- related fatigue in ColoCare, a large cohort of colorectal cancer patients.
Role: Co-I (Figueiredo/Jim, MPI)
Funding Agency: National Institute for Nursing Research
Project Narrative: This will be among the first and most comprehensive studies we are aware of to compare symptom burden between African American and White prostate cancer survivors, and it will be the first to identify modifiable and non-modifiable risk factors for symptom burden in this population. Identifying risk factors for these outcomes will 1) allow us to develop interventions that target risk factors using evidence-based approaches and 2) lead to development of early support interventions for survivors at greatest risk.
Role: Co-I (Gonzalez, MPI)
Funding Agency: National Cancer Institute
Cognitive Aging, Alzheimers disease, and Cancer-related Cognitive Decline
Project Narrative: Cognitive aging is clinically important in the growing older population because cognitive decline can reduce quality of life, decrease function, and lead to social isolation to conceal deficits. Alzheimer’s disease (AD) and cancer-related cognitive decline (CRCD) are common diseases of cognitive aging, and are the most frequent causes of morbidity and mortality in older individuals. We will use existing de-identified data from older breast cancer survivors to test the hypothesis that CRCD shares common risk factors and clinical-pathological features with AD; the results will provide bidirectional insights into mechanisms, prevention and treatment of AD and CRCD.
Role: Co-I (Mandelblatt/Saykin, MPI)
Funding Agency: National Cancer Institute
Polygenic Risk Scores in Child and Adolescent Psychiatry: Ethical, Clinical, and Legal Implications
Project Narrative: The growing discovery of genomic loci associated with psychiatric disorders allows the generation of polygenic risk scores (PRS) which could help identify individuals at increased risk for a psychiatric disorder and potentially prevent or delay disease onset, and minimize morbidity and risk for suicide. However, the use of PRS in child and adolescent psychiatry, and its ethical and legal implications remain understudied. To promote responsible use of psychiatric PRS in children and adolescents, we will use a mixed-methods approach that includes qualitative, quantitative, and legal analysis to: 1) give voice to stakeholders (i.e., patients, parents/caregivers, clinicians) by examining their perspectives regarding whether psychiatric PRS should be used and, if so, how; and 2) examine the legal and regulatory landscape to identify what privacy and genetic discrimination safeguards may be necessary.
Role: Co-I (Pereira/Lazaro-Munoz/Storch, MPI)
Funding Agency: National Institute for Mental Health
Page updated
Google Sites
Report abuse